Vincent Dubois
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincent Dubois has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Analia Azaro
AstraZeneca 19 Early Global Development, Oncology R&D Barcelona, Spain
21 shared publications - Anthony El-Khoueiry
USC Norris Comprehensive Cancer Center, Los Angeles, CA
21 shared publications - Arjun Oberoi
Vall d’Hebron Barcelona Hospital Campus, IIS IR-HUVH, Barcelona, Spain
21 shared publications - Benedito Arruda Carneiro
Legorreta Cancer Center, Brown University, Providence, RI 02912, USA
21 shared publications - Benjamin Ridgway
Oncology R&D, AstraZeneca 17 Early Oncology Clinical Development Gaithersburg, Maryland
21 shared publications - Dmitriy Zamarin
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
21 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Purpose:MEDI1191 is a lipid nanoparticle–formulated messenger RNA (mRNA) designed to induce local interleukin (IL) 12 production and intensify antitumor T-cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). Patients and Methods:Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (parts 1A and 1B) or deep-seated lesions (part 1D) were injected; patients had ≥1 noninjected lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (part 1A) or concurrently (parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy. Results:As of February 27, 2023, 61 patients were treated. Patients had a median of four prior regimens (range, 1–17); 39 (63.9%) received prior anti–programmed cell death protein 1/programmed cell death ligand 1 [PD-(L)1] immunotherapy. Treatment-emergent adverse events (TEAE) occurred in 96.7% of patients, and 41.0% experienced grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. The objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PR). The duration of response was 2.7 to 22.3 months; the median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti–PD-(L)1 therapy had PRs. Conclusions:MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Purpose:MEDI1191 is a lipid nanoparticle–formulated messenger RNA (mRNA) designed to induce local interleukin (IL) 12 production and intensify antitumor T-cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). Patients and Methods:Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (parts 1A and 1B) or deep-seated lesions (part 1D) were injected; patients had ≥1 noninjected lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (part 1A) or concurrently (parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy. Results:As of February 27, 2023, 61 patients were treated. Patients had a median of four prior regimens (range, 1–17); 39 (63.9%) received prior anti–programmed cell death protein 1/programmed cell death ligand 1 [PD-(L)1] immunotherapy. Treatment-emergent adverse events (TEAE) occurred in 96.7% of patients, and 41.0% experienced grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. The objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PR). The duration of response was 2.7 to 22.3 months; the median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti–PD-(L)1 therapy had PRs. Conclusions:MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary References1 from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Supplementary References. References included in the additional supplementary files.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary References1 from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Supplementary References. References included in the additional supplementary files.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Results1 from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Supplementary Results: Pharmacokinetics; Immunogenicity.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Results1 from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Supplementary Results: Pharmacokinetics; Immunogenicity.